Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as F-18 (BAY85-8050)
F-18 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| F-18 (BAY85-8050) | DRUG | Cancer patients, injection of BAY 85-8050, PET/CT |
Inclusion Criteria: * Healthy volunteers only * Males/females, \>/=50 and \</= 65 years of age * Cancer patients only * Males/females \>/= 35 years and \</= 75 years of age * Patient had an FDG PET/CT for detection, or staging, or restaging, or therapy response assessment that still showed tumor ma...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
F-18 is an investigational imaging agent being studied for use in neoplasms, or tumors. It is designed for positron emission tomography and computed tomography, known as PET/CT imaging, to help visualize tumor tissue. It is being developed by Bayer AG and remains in clinical development.
F-18 is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the clinical research evaluating the agent in healthy volunteers and patients with neoplasms.
F-18 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The agent is investigational and has not been approved for commercial use.
F-18 has been evaluated in one completed Phase 1 trial, NCT00961831, titled Radiation Dosimetry, Metabolism, Safety, Tolerability and PET/CT Imaging With BAY 85-8050 in Healthy Volunteers and Patients. The trial enrolled 20 participants in Germany and included healthy volunteers.
Yes, F-18 is also known as BAY85-8050, and the two names refer to the same compound. Bayer AG developed the agent under the BAY85-8050 designation, and it is sometimes written as BAY 85-8050 in trial documentation.